1. KEY INSIGHTS 2. NEUROMYELITIS OPTICA SPECTRUM DISORDER: MARKET OVERVIEW AT A GLANCE 2.1. TOTAL MARKET SHARE (%) DISTRIBUTION OF NEUROMYELITIS OPTICA SPECTRUM DISORDER IN 2017 2.2. TOTAL MARKET SHARE (%) DISTRIBUTION OF NEUROMYELITIS OPTICA SPECTRUM DISORDER IN 2028 3. NEUROMYELITIS OPTICA SPECTRUM DISORDER: DISEASE BACKGROUND AND OVERVIEW 3.1. INTRODUCTION 3.2. SIGNS AND SYMPTOMS 3.3. CLINICAL FEATURES OF NMO/NMOSD 3.4. CLASSIFICATION 3.5. PATHOGENESIS 3.6. DIAGNOSIS 3.7. INTERNATIONAL CONSENSUS DIAGNOSTIC CRITERIA FOR NEUROMYELITIS OPTICA SPECTRUM DISORDERS 3.8. NEUROIMAGING AND NEUROPHYSIOLOGIC TESTING 3.8.1. Considerations for AQP4-IgG serologic and other laboratory testing. 3.8.2. Pediatric NMOSD criteria 3.8.3. Monophasic NMOSD 3.8.4. Systemic autoimmunity associated with NMOSD. 3.8.5. Pathology 3.8.6. Opticospinal MS 4. EPIDEMIOLOGY AND PATIENT POPULATION 4.1. KEY FINDINGS 5. 7MM TOTAL PREVALENT PATIENT POPULATION OF NMO/NMOSD 6. COUNTRY WISE-EPIDEMIOLOGY OF NMO/NMOSD 6.1. UNITED STATES 6.1.1. Assumptions and Rationale 6.1.2. Total Prevalent Population of NMO/NMOSD 6.1.3. Gender-Specific Prevalent Population of NMO/NMOSD 6.1.4. Total Diagnosed Population of NMO/NMOSD 6.1.5. NMO-IgG Diagnosed Cases of NMO/NMOSD 6.1.6. Clinical Characterization of NMO/NMOSD 6.1.7. Events of NMO/NMOSD 6.2. EU5 COUNTRIES 6.2.1. Assumptions and Rationale 6.3. GERMANY 6.3.1. Assumptions and Rationale 6.3.2. Total Prevalent Population of NMO/NMOSD 6.3.3. Gender-Specific Prevalent Population of NMO/NMOSD 6.3.4. Total Diagnosed Population of NMO/NMOSD 6.3.5. NMO-IgG Diagnosed Cases of NMO/NMOSD 6.3.6. Clinical Characterization of NMO/NMOSD 6.3.7. Events of NMO/NMOSD 6.4. FRANCE 6.4.1. Assumptions and Rationale 6.4.2. Total Prevalent Population of NMO/NMOSD 6.4.3. Gender-Specific Prevalent Population of NMO/NMOSD 6.4.4. Total Diagnosed Population of NMO/NMOSD 6.4.5. NMO-IgG Diagnosed Cases of NMO/NMOSD 6.4.6. Clinical Characterization of NMO/NMOSD 6.4.7. Events of NMO/NMOSD 6.5. ITALY 6.5.1. Assumptions and Rationale 6.5.2. Total Prevalent Population of NMO/NMOSD 6.5.3. Gender-Specific Prevalent Population of NMO/NMOSD 6.5.4. Total Diagnosed Population of NMO/NMOSD 6.5.5. NMO-IgG Diagnosed Cases of NMO/NMOSD 6.5.6. Clinical Characterization of NMO/NMOSD 6.5.7. Events of NMO/NMOSD 6.6. UNITED KINGDOM 6.6.1. Assumptions and Rationale 6.6.2. Total Prevalent Population of NMO/NMOSD 6.6.3. Gender-Specific Prevalent Population of NMO/NMOSD 6.6.4. Total Diagnosed Population of NMO/NMOSD 6.6.5. NMO-IgG Diagnosed Cases of NMO/NMOSD 6.6.6. Clinical Characterization of NMO/NMOSD 6.6.7. Events of NMO/NMOSD 6.7. SPAIN 6.7.1. Assumptions and Rationale 6.7.2. Total Prevalent Population of NMO/NMOSD 6.7.3. Gender-Specific Prevalent Population of NMO/NMOSD 6.7.4. Total Diagnosed Population of NMO/NMOSD 6.7.5. NMO-IgG Diagnosed Cases of NMO/NMOSD 6.7.6. Clinical Characterization of NMO/NMOSD 6.7.7. Events of NMO/NMOSD 6.8. JAPAN 6.8.1. Assumptions and Rationale 6.8.2. Total Prevalent Population of NMO/NMOSD 6.8.3. Gender-Specific Prevalent Population of NMO/NMOSD 6.8.4. Total Diagnosed Population of NMO/NMOSD 6.8.5. NMO-IgG Diagnosed Cases of NMO/NMOSD 6.8.6. Clinical Characterization of NMO/NMOSD 6.8.7. Events of NMO/NMOSD 7. TREATMENT 7.1. TREATMENT ALGORITHM 7.1.1. Treatment of Acute Attacks 7.1.2. Preventive Treatment of Relapse 7.2. TREATMENT GUIDELINES COUNTRY WISE 7.2.1. American College of Chest Physicians Task Force 7.2.2. European Federation of Neurological Societies (EFNS) 8. UNMET NEEDS 9. KEY CROSS COMPETITORS 10. EMERGING DRUGS 10.1. INEBILIZUMAB: VIELA BIO 10.1.1. Drug Description 10.1.2. Other Development Activities 10.1.3. Clinical Development 10.1.4. Safety and Efficacy 10.1.5. Product Profile 10.2. SATRALIZUMAB (SA237): CHUGAI PHARMACEUTICAL/ ROCHE 10.2.1. Drug Description 10.2.2. Other Development Activities 10.2.3. Clinical Development 10.2.4. Safety and Efficacy 10.2.5. Product Profile 10.3. SOLIRIS: ALEXION PHARMA 10.3.1. Drug Description 10.3.2. Regulatory Milestones 10.3.3. Clinical Development 10.3.4. Safety and Efficacy 10.3.5. Product Profile 10.4. ULTOMIRIS: ALEXION 10.4.1. Drug Description 10.4.2. Other Development Activities 10.4.3. Product Profile 11. NEUROMYELITIS OPTICA: 7 MAJOR MARKET ANALYSIS 11.1. KEY FINDINGS 11.2. MARKET SIZE OF NMO/NMOSD IN 7MM 12. UNITED STATES MARKET OUTLOOK 12.1. UNITED STATES MARKET SIZE 12.1.1. Total Market size of NMO/NMOSD 12.1.2. Market Size by Therapies for Acute Management of NMO 12.1.3. Market Size by Therapies for Preventive Management of NMO 12.1.4. Market Size by Emerging Therapies 13. EU-5 COUNTRIES: MARKET OUTLOOK 13.1. GERMANY 13.1.1. Total Market size of NMO/NMOSD 13.1.2. Market Size by Therapies for Acute Management of NMO 13.1.3. Market Size by Therapies for Preventive Management of NMO 13.1.4. Market Size by Emerging Therapies 13.2. FRANCE 13.2.1. Total Market size of NMO/NMOSD 13.2.2. Market Size by Therapies for Acute Management of NMO 13.2.3. Market Size by Therapies for Preventive Management of NMO 13.2.4. Market Size by Emerging Therapies 13.3. ITALY 13.3.1. Total Market size of NMO/NMOSD 13.3.2. Market Size by Therapies for Acute Management of NMO 13.3.3. Market Size by Therapies for Preventive Management of NMO 13.3.4. Market Size by Emerging Therapies 13.4. UNITED KINGDOM 13.4.1. Total Market size of NMO/NMOSD 13.4.2. Market Size by Therapies for Acute Management of NMO 13.4.3. Market Size by Therapies for Preventive Management of NMO 13.4.4. Market Size by Emerging Therapies 13.5. SPAIN 13.5.1. Total Market size of NMO/NMOSD 13.5.2. Market Size by Therapies for Acute Management of NMO 13.5.3. Market Size by Therapies for Preventive Management of NMO 13.5.4. Market Size by Emerging Therapies 14. JAPAN: MARKET OUTLOOK 14.1. JAPAN MARKET SIZE 14.1.1. Total Market size of NMO/NMOSD 14.1.2. Market Size by Therapies for Acute Management of NMO 14.1.3. Market Size by Therapies for Preventive Management of NMO 14.1.4. Market Size by Emerging Therapies 15. MARKET DRIVERS 16. MARKET BARRIERS 17. APPENDIX 17.1. REPORT METHODOLOGY 18. DELVEINSIGHT CAPABILITIES 19. DISCLAIMER 20. ABOUT DELVEINSIGHT

Table 1: Signs and Symptoms of Neuromyelitis Optica Table 2: Brain symptoms in Neuromyelitis Optica Table 3: NMOSD diagnostic criteria for adult patients Table 4: Red flags: Findings atypical for NMOSD Table 5: Neuroimaging characteristics of NMOSD Table 6: Total Prevalent Population of NMO/NMOSD in the 7MM (2017-2028) Table 7: Total Prevalent Population of NMO/NMOSD in the US (2017-2028) Table 8: Gender Specific Prevalence of NMO/NMOSD in the US (2017-2028) Table 9: Diagnosed Cases of Neuromyelitis Optica in the US (2017-2028) Table 10: NMO-IgG Diagnosed Cases of NMO/NMOSD in the US (2017-2028) Table 11: Clinical Characterization of NMO/NMOSD in the US (2017-2028) Table 12: Events of NMO/NMOSD in the US (2017-2028) Table 13: Total Prevalent Population of NMO/NMOSD in Germany (2017-2028) Table 14: Gender Specific Prevalence of NMO/NMOSD in Germany (2017-2028) Table 15: Diagnosed Cases of Neuromyelitis Optica in Germany (2017-2028) Table 16: NMO-IgG Diagnosed Cases of NMO/NMOSD in Germany (2017-2028) Table 17: Clinical Characterization of NMO/NMOSD in Germany (2017-2028) Table 18: Events of NMO/NMOSD in Germany (2017-2028) Table 19: Total Prevalent Population of NMO/NMOSD in France (2017-2028) Table 20: Gender Specific Prevalence of NMO/NMOSD in France (2017-2028) Table 21: Diagnosed Cases of Neuromyelitis Optica in France (2017-2028) Table 22: NMO-IgG Diagnosed Cases of NMO/NMOSD in France (2017-2028) Table 23: Clinical Characterization of NMO/NMOSD in France (2017-2028) Table 24: Events of NMO/NMOSD in France (2017-2028) Table 25: Total Prevalent Population of NMO/NMOSD in Italy (2017-2028) Table 26: Gender Specific Prevalence of NMO/NMOSD in Italy (2017-2028) Table 27: Diagnosed Cases of Neuromyelitis Optica in Italy (2017-2028) Table 28: NMO-IgG Diagnosed Cases of NMO/NMOSD in Italy (2017-2028) Table 29: Clinical Characterization of NMO/NMOSD in Italy (2017-2028) Table 30: Events of NMO/NMOSD in Italy (2017-2028) Table 31: Total Prevalent Population of NMO/NMOSD in The UK (2017-2028) Table 32: Gender Specific Prevalence of NMO/NMOSD in The UK (2017-2028) Table 33: Diagnosed Cases of Neuromyelitis Optica in The UK (2017-2028) Table 34: NMO-IgG Diagnosed Cases of NMO/NMOSD in the UK (2017-2028) Table 35: Clinical Characterization of NMO/NMOSD in The UK (2017-2028) Table 36: Events of NMO/NMOSD in The UK (2017-2028) Table 37: Total Prevalent Population of NMO/NMOSD in Spain (2017-2028) Table 38: Gender Specific Prevalence of NMO/NMOSD in Spain (2017-2028) Table 39: Diagnosed Cases of Neuromyelitis Optica in Spain (2017-2028) Table 40: NMO-IgG Diagnosed Cases of NMO/NMOSD in Spain (2017-2028) Table 41: Clinical Characterization of NMO/NMOSD in Spain (2017-2028) Table 42: Events of NMO/NMOSD in Spain (2017-2028) Table 43: Total Prevalent Population of NMO/NMOSD in Japan (2017-2028) Table 44: Gender Specific Prevalence of NMO/NMOSD in Japan (2017-2028) Table 45: Diagnosed Cases of Neuromyelitis Optica in Japan (2017-2028) Table 46: NMO-IgG Diagnosed Cases of NMO/NMOSD in Japan (2017-2028) Table 47: Clinical Characterization of NMO/NMOSD in Japan (2017-2028) Table 48: Events of NMO/NMOSD in Japan (2017-2028) Table 49: Grading Recommendations for Neuromyelitis Optica Table 50: Summary of treatments and recommendation levels used for Neuromyelitis Optica Table 51: Inebilizumab, Clinical Trial Description, 2019 Table 52: Satralizumab, Clinical Trial Description, 2019 Table 53: Eculizumab, Clinical Trial Description, 2019 Table 54: 7 Major Market Size of NMO/NMOSD in USD Million (2017-2028) Table 55: Market Size of NMO/NMOSD in the US, USD Million (2017-2028) Table 56: Market Size by Therapies for Acute Management of NMO in the US, USD Million (2017-2028) Table 57: Market Size by Therapies for Preventive Management of NMO in the US, in USD Million (2017-2028) Table 58: Market Size by Emerging Therapies in the US, in USD Million (2017-2028) Table 59: Market Size of NMO/NMOSD in Germany, USD Million (2017-2028) Table 60: Market Size by Therapies for Acute Management of NMO in Germany, USD Million (2017-2028) Table 61: Market Size by Therapies for Preventive Management of NMO in Germany, in USD Million (2017-2028) Table 62: Market Size by Emerging Therapies in Germany, in USD Million (2017-2028) Table 63: Market Size of NMO/NMOSD in France, USD Million (2017-2028) Table 64: Market Size by Therapies for Acute Management of NMO in France, USD Million (2017-2028) Table 65: Market Size by Therapies for Preventive Management of NMO in France, in USD Million (2017-2028) Table 66: Market Size by Emerging Therapies in France, in USD Million (2017-2028) Table 67: Market Size of NMO/NMOSD in Italy, USD Million (2017-2028) Table 68: Market Size by Therapies for Acute Management of NMO in Italy, USD Million (2017-2028) Table 69: Market Size by Therapies for Preventive Management of NMO in Italy, in USD Million (2017-2028) Table 70: Market Size by Emerging Therapies in Italy, in USD Million (2017-2028) Table 71: Market Size of NMO/NMOSD in the UK, USD Million (2017-2028) Table 72: Market Size by Therapies for Acute Management of NMO in the UK, USD Million (2017-2028) Table 73: Market Size by Therapies for Preventive Management of NMO in the UK, in USD Million (2017-2028) Table 74: Market Size by Emerging Therapies in the UK, in USD Million (2017-2028) Table 75: Market Size of NMO/NMOSD in Spain, USD Million (2017-2028) Table 76: Market Size by Therapies for Acute Management of NMO in Spain, USD Million (2017-2028) Table 77: Market Size by Therapies for Preventive Management of NMO in Spain, in USD Million (2017-2028) Table 78: Market Size by Emerging Therapies in Spain, in USD Million (2017-2028) Table 79: Market Size of NMO/NMOSD in Japan, USD Million (2017-2028) Table 80: Market Size by Therapies for Acute Management of NMO in Japan, USD Million (2017-2028) Table 81: Market Size by Therapies for Preventive Management of NMO in Japan, in USD Million (2017-2028) Table 82: Market Size by Emerging Therapies in Japan, in USD Million (2017-2028) Figure 1: Signs and symptoms of NMO/NMOSD Figure 2: Clinical features of NMO/NMOSD Figure 3: Neuromyelitis Optica Pathogenesis Figure 4: Total Prevalent Patient Population of NMO/NMOSD in the 7MM (2017-2028) Figure 5: Total Prevalent Population of NMO/NMOSD in the US (2017-2028) Figure 6: Gender Specific Prevalence of NMO/NMOSD in the US (2017-2028) Figure 7: Diagnosed Cases of NMO/NMOSD in the US (2017-2028) Figure 8: NMO-IgG Diagnosed Cases of NMO/NMOSD in the US (2017-2028) Figure 9: Clinical Characterization of NMO/NMOSD in the US (2017-2028) Figure 10: Events of NMO/NMOSD in the US (2017-2028) Figure 11: Total Prevalent Population of NMO/NMOSD in Germany (2017-2028) Figure 12: Gender Specific Prevalence of NMO/NMOSD in Germany (2017-2028) Figure 13: Diagnosed Cases of NMO/NMOSD in Germany (2017-2028) Figure 14: NMO-IgG Diagnosed Cases of NMO/NMOSD in Germany (2017-2028) Figure 15: Clinical Characterization of NMO/NMOSD in Germany (2017-2028) Figure 16: Events of NMO/NMOSD in Germany (2017-2028) Figure 17: Total Prevalent Population of NMO/NMOSD in France (2017-2028) Figure 18: Gender Specific Prevalence of NMO/NMOSD in France (2017-2028) Figure 19: Diagnosed Cases of NMO/NMOSD in France (2017-2028) Figure 20: NMO-IgG Diagnosed Cases of NMO/NMOSD in France (2017-2028) Figure 21: Clinical Characterization of NMO/NMOSD in France (2017-2028) Figure 22: Events of NMO/NMOSD in France (2017-2028) Figure 23: Total Prevalent Population of NMO/NMOSD in Italy (2017-2028) Figure 24: Gender Specific Prevalence of NMO/NMOSD in Italy (2017-2028) Figure 25: Diagnosed Cases of NMO/NMOSD in Italy (2017-2028) Figure 26: NMO-IgG Diagnosed Cases of NMO/NMOSD in Italy (2017-2028) Figure 27: Clinical Characterization of NMO/NMOSD in Italy (2017-2028) Figure 28: Events of NMO/NMOSD in Italy (2017-2028) Figure 29: Total Prevalent Population of NMO/NMOSD in The UK (2017-2028) Figure 30: Gender Specific Prevalence of NMO/NMOSD in The UK (2017-2028) Figure 31: Diagnosed Cases of NMO/NMOSD in The UK (2017-2028) Figure 32: NMO-IgG Diagnosed Cases of NMO/NMOSD in the UK (2017-2028) Figure 33: Clinical Characterization of NMO/NMOSD in The UK (2017-2028) Figure 34: Events of NMO/NMOSD in The UK (2017-2028) Figure 35: Total Prevalent Population of NMO/NMOSD in Spain (2017-2028) Figure 36: Gender Specific Prevalence of NMO/NMOSD in Spain (2017-2028) Figure 37: Diagnosed Cases of NMO/NMOSD in Spain (2017-2028) Figure 38: NMO-IgG Diagnosed Cases of NMO/NMOSD in Spain (2017-2028) Figure 39: Clinical Characterization of NMO/NMOSD in Spain (2017-2028) Figure 40: Events of NMO/NMOSD in Spain (2017-2028) Figure 41: Total Prevalent Population of NMO/NMOSD in Japan (2017-2028) Figure 42: Gender Specific Prevalence of NMO/NMOSD in Japan (2017-2028) Figure 43: Diagnosed Cases of NMO/NMOSD in Japan (2017-2028) Figure 44: NMO-IgG Diagnosed Cases of NMO/NMOSD in Japan (2017-2028) Figure 45: Clinical Characterization of NMO/NMOSD in Japan (2017-2028) Figure 46: Events of NMO/NMOSD in Japan (2017-2028) Figure 47: Treatment Algorithm of Neuromyelitis Optica Figure 48: Unmet Needs of Neuromyelitis Optica Figure 49: 7 Major Market Size of NMO/NMOSD in USD Million (2017-2028) Figure 50: Market Size of NMO/NMOSD in the US, USD Million (2017-2028) Figure 51: Market Size by Therapies for Acute Management of NMO in the US, USD Million (2017-2028) Figure 52: Market Size by Therapies for Preventive Management of NMO in the US, in USD Million (2017-2028) Figure 53: Market Size by Emerging Therapies in the US, in USD Million (2017-2028) Figure 54: Market Size of NMO/NMOSD in Germany, USD Million (2017-2028) Figure 55: Market Size by Therapies for Acute Management of NMO in Germany, USD Million (2017-2028) Figure 56: Market Size by Therapies for Preventive Management of NMO in Germany, in USD Million (2017-2028) Figure 57: Market Size by Emerging Therapies in Germany, in USD Million (2017-2028) Figure 58: Market Size of NMO/NMOSD in France, USD Million (2017-2028) Figure 59: Market Size by Therapies for Acute Management of NMO in France, USD Million (2017-2028) Figure 60: Market Size by Therapies for Preventive Management of NMO in France, in USD Million (2017-2028) Figure 61: Market Size by Emerging Therapies in France, in USD Million (2017-2028) Figure 62: Market Size of NMO/NMOSD in Italy, USD Million (2017-2028) Figure 63: Market Size by Therapies for Acute Management of NMO in Italy, USD Million (2017-2028) Figure 64: Market Size by Therapies for Preventive Management of NMO in Italy, in USD Million (2017-2028) Figure 65: Market Size by Emerging Therapies in the Italy, in USD Million (2017-2028) Figure 66: Market Size of NMO/NMOSD in the UK, USD Million (2017-2028) Figure 67: Market Size by Therapies for Acute Management of NMO in the UK, USD Millions (2017-2028) Figure 68: Market Size by Therapies for Preventive Management of NMO in the UK, in USD Million (2017-2028) Figure 69: Market Size by Emerging Therapies in the UK, in USD Million (2017-2028) Figure 70: Market Size of NMO/NMOSD in Spain, USD Million (2017-2028) Figure 71: Market Size by Therapies for Acute Management of NMO in Spain, USD Million (2017-2028) Figure 72: Market Size by Therapies for Preventive Management of NMO in Spain, in USD Million (2017-2028) Figure 73: Market Size by Emerging Therapies in Spain, in USD Million (2017-2028) Figure 74: Market Size of NMO/NMOSD in Japan, USD Million (2017-2028) Figure 75: Market Size by Therapies for Acute Management of NMO in Japan, USD Million (2017-2028) Figure 76: Market Size by Therapies for Preventive Management of NMO in Japan, in USD Million (2017-2028) Figure 77: Market Size by Emerging Therapies in Japan, in USD Million (2017-2028) Figure 78: Market Drivers Figure 79: Market Barriers

1. VIELA BIO 2. CHUGAI PHARMACEUTICAL/ ROCHE 3. ALEXION PHARMA 4. ALEXION And Others